HopeStage
Back to all studies
TerminatedNCT01756053

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
PhiladelphiaSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateMarch 2013
Recruitment status
Terminated
Enrollment listed in the registry
17
Sponsor
University of Pennsylvania
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT01756053
Official title
Show the full official title

A Pilot Feasibility Study of the Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

Recruitment & locations

Terminated

Philadelphia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Pennsylvania, a university.

Does this study involve medication?

Yes. The study involves medication, including ABT-089 and Placebo.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies